The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal ...

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

Papa presented the company’s “turnaround plan” for 2025 at J.P. Morgan. “We are focused on first stabilising the company, ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

Monica Johnson, Psy.D., is a clinical psychologist and owner of Kind Mind Psychology, a private practice in NYC that specializes in evidenced-based approaches to treating a wide range of mental ...

Prism Johnson Ltd., incorporated in the year 1992, is a Mid Cap company (having a market cap of Rs 7,203.54 Crore) operating in Cement sector. Prism Johnson Ltd. key Products/Revenue Segments include ...